Keywords: ومورفنیب; allergic reaction; antitumor response; antitumor response toxic epidermal necrolysis; BRAF inhibitor; BRAF inhibitor Stevens-Johnson syndrome; BRAF inhibitor toxic epidermal necrolysis; coBRIM allergic reaction; coBRIM adverse effect; coBRIM hypersensitiv
مقالات ISI ومورفنیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ومورفنیب; Cladribine; HCL treatment; Rituximab; Treatment efficacy; Vemurafenib;
Keywords: ومورفنیب; Vemurafenib; Melanoma; Liposome; Peptide; Transdermal delivery;
Keywords: ومورفنیب; Erdheim-Chester disease; BRAF V600E mutation; Vemurafenib;
Keywords: ومورفنیب; Melanoma; Nanotechnology; Nanoparticles; Chemotherapy; Immunotherapy; Drug resistance; Vemurafenib; Dabrafenib; Ipilimumab;
Keywords: ومورفنیب; Erdheim-Chester disease; Histiocytosis; Diagnosis; Treatment; BRAF gene; Vemurafenib
Keywords: ومورفنیب; Erdheim–Chester disease; CNS involvement; Histiocytosis; BRAFV600E; Vemurafenib
Keywords: ومورفنیب; Vemurafenib; LC-MS/MS; Plasma; GLP; Validation;
Keywords: ومورفنیب; Melanoma; Brain metastases; Vemurafenib; Dabrafenib; BRAF; Ipilimumab; Blood brain barrier;
Keywords: ومورفنیب; Vemurafenib; Melanoma; Drug resistance; Toxicity; Squamous cell carcinoma; Combination therapy;
Keywords: ومورفنیب; BRAF inhibitor; drug reaction; erythema nodosum; melanoma; panniculitis; vemurafenib
Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib
Keywords: ومورفنیب; Histiocytosis; Vemurafenib; Orbital; Chorioretinal; Xanthomatous; Lipogranulomatous; BRAF;
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
Keywords: ومورفنیب; Antibody-drug conjugate (ADC); HER-3; Melanoma; BRAF; Vemurafenib;
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Keywords: ومورفنیب; Melanoma; Chemotherapy; Vemurafenib; Dabrafenib; Trametinib; Metastatic; Unresectable; BRAF inhibitor; MEK inhibitor; Progression free survival (PFS); Median progression free survival;
miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma
Keywords: ومورفنیب; miR-216b; Vemurafenib; Autophagy; Beclin-1; UVRAG; ATG5;
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Keywords: ومورفنیب; Non-small cell lung cancer (NSCLC); BRAF mutations; Mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway; Vemurafenib; Dabrafenib; Trametinib;
Communication brèveHistiocytose langerhansienne et maladie d'Erdheim-Chester, une continuité ?Langerhans cell histiocytosis and Erdheim-Chester disease, a continuity?
Keywords: ومورفنیب; Maladie d'Erdheim-Chester; Histiocytose langerhansienne; BRAF; Vemurafenib; Erdheim-Chester disease; Langerhans cell histiocytosis; BRAF; Vemurafenib;
Original ArticleBIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines
Keywords: ومورفنیب; Melanoma; Vemurafenib; Trametinib; BIK/NBK; Apoptosis;
Original ResearchOpen-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
Keywords: ومورفنیب; BRAFV600 mutation; Metastatic melanoma; Vemurafenib; Safety;
(Neo)adjuvant systemic therapy for melanoma
Keywords: ومورفنیب; Cutaneous melanoma; High risk melanoma; Melanoma; Adjuvant; Neoadjuvant; Immunotherapy; Anti CTLA-4; Ipilimumab; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK inhibitor; Trametinib; Cobimetinib; Anti PD1; T-VEC; Tamilogene Laherparepvec; Review;
Original ResearchThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Keywords: ومورفنیب; Dabrafenib; Trametinib; Vemurafenib; Melanoma; Multivariate analysis;
Original ArticleEverolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
Keywords: ومورفنیب; Acidosis; Tumor microenvironment; BRAFV600E melanoma cells; Vemurafenib; Trametinib; Everolimus; MAPK; mitogen-activated protein kinase; RTK; receptor tyrosine kinases; ERK; extracellular signal-regulated kinases; PI3K; phosphatidylinositol 3-kinase; AKT;
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
Keywords: ومورفنیب; BRAFi; BRAF inhibitors; MEKi; MEK inhibitors; Cmin; Trough concentration; CV; Coefficient of variation; EMA; European Medical Agency; ESI; Electrospray ionization; LC-UV; Liquid chromatography combined to UV detection; LLOQ; Low limit of quantification; M
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: ومورفنیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene
Keywords: ومورفنیب; Adenocarcinoma; Cancer personalized profiling; Targeted therapy; Vemurafenib;
Métastases cutanées d'un mélanome sur un territoire de radiothérapie au niveau du sein : traitement par vémurafénib et chirurgie d'exérèse large
Keywords: ومورفنیب; Métastases cutanées; Mélanome; Champ d'irradiation; Radiothérapie; Vémurafénib; BRAFV600E; Survie; Cancer du sein; Immunomodulation; Cutaneous metastasis; Melanoma; Irradiation territory; Radiotherapie; Vemurafenib; BRAFV600E; Survival; Breast can
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review
Keywords: ومورفنیب; Melanoma; Brain metastases; Vemurafenib; Dabrafenib; Ipilimumab; Survival;
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Keywords: ومورفنیب; V600E/KBRAF; Vemurafenib; p53; PRIMA-1Met; Drug resistance; Melanoma;
Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti-BRAF V600 Inhibitors
Keywords: ومورفنیب; Dabrafenib; Ivermectin; MAPK; PAK1; Vemurafenib;
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
Keywords: ومورفنیب; β-catenin; Melanoma; BRAF; Stat3; Resistance; Vemurafenib
Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation
Keywords: ومورفنیب; BRAF; v-Raf murine sarcoma viral oncogene homolog B; MAPK; mitogen-activated protein kinases; MMP; matrix metalloproteinase; ECM; extracellular matrix; IL-8; interleukin 8; EGFR; epidermal growth factor receptor; TIMP-2; metallopeptidase-2 or tissue inhib
Hairy cell leukemia: Past, present and future
Keywords: ومورفنیب; Hairy cell leukemia; BRAF; Vemurafenib;
The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing
Keywords: ومورفنیب; Vemurafenib; Phototoxicity; Monochromator phototesting; Porphyrin
BRAF inhibitor therapy in HCL
Keywords: ومورفنیب; Hairy cell leukemia; BRAF V600E; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK;
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Keywords: ومورفنیب; Lung cancer; Targeted therapy; BRAF; Vemurafenib; Dabrafenib;
BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
Keywords: ومورفنیب; BRAF; Vemurafenib; B-cell; ABCB1; P-glycoprotein; Leukemia; Lymphoma;
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Keywords: ومورفنیب; BRAF; Vemurafenib; Dabrafenib; Resistance; Acquired; MAPK; NRAS; Splice; MEK1; Meta-analysis
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer
Keywords: ومورفنیب; BRAF; V600E; MEK; Vemurafenib; Dabrafenib; Trametinib; Non-small-cell lung cancer;
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Keywords: ومورفنیب; Melanoma; BRAF; MEK; Vemurafenib; Dabrafenib; Trametinib
Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Keywords: ومورفنیب; Vemurafenib; BRAF inhibitor; Metastatic melanoma;
Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
Keywords: ومورفنیب; Cutaneous melanoma; Vemurafenib; BRAF inhibitor; Treatment beyond progression; Overall survival;
The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
Keywords: ومورفنیب; Vemurafenib; TGFβ; pERK; IL-8; MMP-1; Human melanoma; Murine melanoma;
Rôle de la TEP/TDM au 18FDG dans la caractérisation et le suivi thérapeutique des histiocytoses
Keywords: ومورفنیب; Histiocytoses; Maladie d’Erdheim-Chester; 18FDG-TEP; Traitement; VémurafenibHistiocytoses; Erdheim–Chester disease; FDG-PET/CT; Immunomodulators; Vemurafenib
Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling
Keywords: ومورفنیب; Next generation sequencing (NGS); Ion torrent; Nanopore; Cancer modelling history; Tumour clonality; Cytoxic chemotherapy; Gene networks; Targeted gene therapy (TGT); Imatinib; Chronic myelogenous leukaemia (CML); Vemurafenib; Melanoma; Non small cell lun
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib
Keywords: ومورفنیب; MC3181; 2-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol; NBDHEX; 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol; NBD; nitrobenzoxadiazole; MBP; microprecipitated bulk powder; GST; glutathione transferase; (MRP); multidr
BRAF V600E Mutation and Clonal Evolution in a Patient With Relapsed Refractory Myeloma With Plasmablastic Differentiation
Keywords: ومورفنیب; BRAF mutation; Multiple myeloma; Relapse; Refractory; Vemurafenib;
A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients
Keywords: ومورفنیب; Vemurafenib; Plasma; LC–MS/MS; Pharmacokinetic; Melanoma
Deux cas de dermatose acantholytique sous vémurafénib
Keywords: ومورفنیب; Mélanome; Vémurafénib; Dermatose acantholytique; Grover; Effets secondaires des médicaments; Melanoma; Vemurafenib; Acantholytic dyskeratosis; Grover; Drug adverse effects;
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
Keywords: ومورفنیب; BRAF mutation; Lung adenocarcinoma; Brain metastasis; Vemurafenib; Non-small cell lung cancer; Targeted therapy;
Comparaison de deux méthodes de mesure des TLG en TEP au 18-FDG dans le mélanome métastatique
Keywords: ومورفنیب; Mélanome; Total lesion glycolysis - TLG; TEP au 18-fluorodesoxyglucose; MIP-based segmentation; PETVCAR; VémurafenibMelanoma; Total lesion glycolysis - TLG; TEP using 18-fluorodesoxyglucose; MIP-based segmentation; PETVCAR; Vemurafenib